Indeed, the frequency of KRAS, NRAS and BRAF mutations increases from 24% in SMM [129], to 50% in newly diagnosed MM, and up to 72% among MM cases refractory to proteasome inhibitors (PIs) and/or immunomodulatory drugs (IMiDs) [130]. This evidence concerns the gene KRAS and Miyoshi myopathy.